2022
Turner, R. M., Magavern, E. F., & Pirmohamed, M. (2022). Pharmacogenomics: Relevance and opportunities for clinical pharmacology. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 88(9), 3943-3946. doi:10.1111/bcp.15329DOI: 10.1111/bcp.15329
Asiimwe, I. G., Pushpakom, S. P., Turner, R. M., Kolamunnage-Dona, R., Jorgensen, A. L., & Pirmohamed, M. (2022). Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 88(8), 3577-3599. doi:10.1111/bcp.15331DOI: 10.1111/bcp.15331
Magavern, E. F., Kaski, J. C., Turner, R. M., Drexel, H., Janmohamed, A., Scourfield, A., . . . Caulfield, M. J. (2022). The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 8(1), 85-99. doi:10.1093/ehjcvp/pvab018DOI: 10.1093/ehjcvp/pvab018
2021
Asiimwe, I. G., Pushpakom, S., Turner, R. M., Kolamunnage-Dona, R., Jorgensen, A. L., & Pirmohamed, M. (2021). Cardiovascular drugs and COVID-19 clinical outcomes: A living systematic review and meta-analysis. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(12), 4534-+. doi:10.1111/bcp.14927DOI: 10.1111/bcp.14927
Magavern, E. F., Kaski, J. C., Turner, R. M., Janmohamed, A., Borry, P., & Pirmohamed, M. (2021). The Interface of Therapeutics and Genomics in Cardiovascular Medicine. CARDIOVASCULAR DRUGS AND THERAPY, 35(3), 663-676. doi:10.1007/s10557-021-07149-3DOI: 10.1007/s10557-021-07149-3
Carr, D. F., Turner, R. M., & Pirmohamed, M. (2021). Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(2), 237-255. doi:10.1111/bcp.14407DOI: 10.1111/bcp.14407
2020
Turner, R. M., de Koning, E. M., Fontana, V., Thompson, A., & Pirmohamed, M. (2020). Multimorbidity, polypharmacy, and drug-drug-gene interactions following a non-ST elevation acute coronary syndrome: analysis of a multicentre observational study. BMC MEDICINE, 18(1). doi:10.1186/s12916-020-01827-zDOI: 10.1186/s12916-020-01827-z
Rollinson, V., Turner, R., & Pirmohamed, M. (2020). Pharmacogenomics for Primary Care: An Overview. GENES, 11(11). doi:10.3390/genes11111337DOI: 10.3390/genes11111337
Turner, R. M., Newman, W. G., Bramon, E., McNamee, C. J., Wong, W. L., Misbah, S., . . . Pirmohamed, M. (2020). Pharmacogenomics in the UK National Health Service: opportunities and challenges. Pharmacogenomics, 21(17), 1237-1246. doi:10.2217/pgs-2020-0091DOI: 10.2217/pgs-2020-0091
Taylor, C., Crosby, I., Yip, V., Maguire, P., Pirmohamed, M., & Turner, R. M. (2020). A Review of the Important Role of CYP2D6 in Pharmacogenomics. GENES, 11(11). doi:10.3390/genes11111295DOI: 10.3390/genes11111295
Turner, R. M., Fontana, V., Zhang, J. E., Carr, D., Yin, P., FitzGerald, R., . . . Pirmohamed, M. (2020). A Genome‐wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites. Clinical Pharmacology and Therapeutics, 108(2), 287-297. doi:10.1002/cpt.1820DOI: 10.1002/cpt.1820
Pharmacogenetics and statin-related myopathy: what do we know? (Journal article)
Turner, R. M., Radman, I., Bozina, N., & Alfirevic, A. (2020). Pharmacogenetics and statin-related myopathy: what do we know?. PHARMACOGENOMICS, 21(12), 821-825. doi:10.2217/pgs-2020-0041DOI: 10.2217/pgs-2020-0041
Carr, D., Turner, R. M., & Pirmohamed, M. (n.d.). Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response. British Journal of Clinical Pharmacology. doi:10.1111/bcp.14407DOI: 10.1111/bcp.14407
van der Wouden, C. H., Bohringer, S., Cecchin, E., Cheung, K. -C., Lucia Davila-Fajardo, C., Deneer, V. H. M., . . . Consor, U. P. (2020). Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. Pharmacogenetics and Genomics, 30(6), 131-144. doi:10.1097/FPC.0000000000000405DOI: 10.1097/FPC.0000000000000405
Turner, R. M., Fontana, V., FitzGerald, R., Morris, A. P., & Pirmohamed, M. (2020). Investigating the clinical factors and comedications associated with circulating levels of atorvastatin and its major metabolites in secondary prevention. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 86(1), 62-74. doi:10.1111/bcp.14133DOI: 10.1111/bcp.14133
2019
Turner, R. M., & Pirmohamed, M. (2020). Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components. JOURNAL OF CLINICAL MEDICINE, 9(1). doi:10.3390/jcm9010022DOI: 10.3390/jcm9010022
Turner, R. M., Genomics England Research Consortium., & Pirmohamed, M. (2019). Pharmacogene variation in the UK 100,000 Genomes Project: an analysis of 60,221 individuals. Poster session presented at the meeting of Genomics England Research Conference. London, UK.
Just, K. S., Turner, R. M., Dolzan, V., Cecchin, E., Swen, J. J., Gurwitz, D., & Stingl, J. C. (2019). Educating the Next Generation of Pharmacogenomics Experts: Global Educational Needs and Concepts. CLINICAL PHARMACOLOGY & THERAPEUTICS, 106(2), 313-316. doi:10.1002/cpt.1471DOI: 10.1002/cpt.1471
2018
Turner, R. M., Fontana, V., Bayliss, M., Whalley, S., Castelazo, A. S., & Pirmohamed, M. (2018). Development, validation and application of a novel HPLC-MS/MS method for the quantification of atorvastatin, bisoprolol and clopidogrel in a large cardiovascular patient cohort. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 159, 272-281. doi:10.1016/j.jpba.2018.06.062DOI: 10.1016/j.jpba.2018.06.062
Pharmacogenetics and Pharmacogenomics in Cardiovascular Medicine and Surgery (Chapter)
Turner, R. M., & Pirmohamed, S. M. (2018). Pharmacogenetics and Pharmacogenomics in Cardiovascular Medicine and Surgery. In Cardiovascular Genetics and Genomics (pp. 119-172). Springer International Publishing. doi:10.1007/978-3-319-66114-8_5DOI: 10.1007/978-3-319-66114-8_5
2017
Turner, R. M. (2017, December 15). Statin-associated muscle toxicity: clinical and genomic perspectives.
van der Wouden, C. H., Cambon-Thomsen, A., Cecchin, E., Cheung, K. C., Davila-Fajardo, C. L., Deneer, V. H., . . . Guchelaar, H. -J. (2017). Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium (vol 101, pg 341, 2017). CLINICAL PHARMACOLOGY & THERAPEUTICS, 102(1), 152. doi:10.1002/cpt.725DOI: 10.1002/cpt.725
van der Wouden, C. H., Cambon-Thomsen, A., Cecchin, E., Cheung, K. C., Davila-Fajardo, C. L., Deneer, V. H., . . . Guchelaar, H. -J. (2017). Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. CLINICAL PHARMACOLOGY & THERAPEUTICS, 101(3), 341-358. doi:10.1002/cpt.602DOI: 10.1002/cpt.602
Turner, R. M., Bayliss, M., Carr, D., Kitteringham, N., Henderson, C., & Pirmohamed, M. (2016, December 13). The impact of P450 oxidoreductase knock out on systemic exposure to rosuvastatin, atorvastatin and atorvastatin metabolites. In http://www.pa2online.org/abstract/abstract.jsp?abid=33238&kw=P450%20oxidoreductase&cat=-1&period=-1. London, UK.
Turner, R. M., Yin, P., Hanson, A., FitzGerald, R., Morris, A. P., Stables, R. H., . . . Pirmohamed, M. (2017). Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome. Journal of Clinical Lipidology, 11(1), 204-214. doi:10.1016/j.jacl.2016.12.007DOI: 10.1016/j.jacl.2016.12.007
2016
Yin, P., Jorgensen, A., Morris, A., Turner, R., Fitzgerald, R., Stables, R., . . . Pirmohamed, M. (2016). SNP-Treatment Interactions of Cardiovascular Medications and Risk of Acute Coronary Syndrome Recurrence. In GENETIC EPIDEMIOLOGY Vol. 40 (pp. 672). Retrieved from https://www.webofscience.com/
Personalized Medicine in Cardiovascular Disease (Chapter)
Turner, R. M., Bula, M., & Pirmohamed, M. (2017). Personalized Medicine in Cardiovascular Disease. In DIAGNOSTIC MOLECULAR PATHOLOGY: A GUIDE TO APPLIED MOLECULAR TESTING (pp. 457-471). doi:10.1016/B978-0-12-800886-7.00036-4DOI: 10.1016/B978-0-12-800886-7.00036-4
2015
Turner, R. M., Park, B. K., & Pirmohamed, M. (2015). Parsing interindividual drug variability: an emerging role for systems pharmacology. WILEY INTERDISCIPLINARY REVIEWS-SYSTEMS BIOLOGY AND MEDICINE, 7(4), 221-241. doi:10.1002/wsbm.1302DOI: 10.1002/wsbm.1302
Pharmacogenetics of Adverse Drug Reactions (Chapter)
Turner, R. M., & Pirmohamed, M. (2015). Pharmacogenetics of Adverse Drug Reactions. In PREVENTIVE AND PREDICTIVE GENETICS: TOWARDS PERSONALISED MEDICINE (Vol. 9, pp. 109-156). doi:10.1007/978-3-319-15344-5_6DOI: 10.1007/978-3-319-15344-5_6
The Influence of Pharmacogenetics on the Time to Acute Coronary Syndrome Recurrence in a UK Cohort Study (Conference Paper)
Yin, P., Jorgensen, A., Morris, A., Turner, R., Fitzgerald, R., Stables, R., . . . Pirmohamed, M. (2015). The Influence of Pharmacogenetics on the Time to Acute Coronary Syndrome Recurrence in a UK Cohort Study. In HUMAN HEREDITY Vol. 80 (pp. 123). Retrieved from https://www.webofscience.com/
2014
Turner, R. M., & Pirmohamed, M. (2014). Cardiovascular Pharmacogenomics: Expectations and Practical Benefits. CLINICAL PHARMACOLOGY & THERAPEUTICS, 95(3), 281-293. doi:10.1038/clpt.2013.234DOI: 10.1038/clpt.2013.234
Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis (Journal article)
Turner, R. M., Kwok, C. S., Chen-Turner, C., Maduakor, C. A., Singh, S., & Loke, Y. K. (2014). Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 78(2), 258-273. doi:10.1111/bcp.12306DOI: 10.1111/bcp.12306
2013
Evaluating Predictive Pharmacogenetic Signatures of Adverse Events in Colorectal Cancer Patients Treated with Fluoropyrimidines (Journal article)
Jennings, B. A., Loke, Y. K., Skinner, J., Keane, M., Chu, G. S., Turner, R., . . . Willis, G. (n.d.). Evaluating Predictive Pharmacogenetic Signatures of Adverse Events in Colorectal Cancer Patients Treated with Fluoropyrimidines. PLoS ONE, 8(10), e78053. doi:10.1371/journal.pone.0078053DOI: 10.1371/journal.pone.0078053
Dose and duration relationship between pioglitazone and associated risk of bladder cancer: a systematic review and meta-analysis (Conference Paper)
Singh, S., Loke, Y., Kwok, C. S., Chen-Turner, C., Turner, R. M., & Maduakor, C. A. (2013). Dose and duration relationship between pioglitazone and associated risk of bladder cancer: a systematic review and meta-analysis. In Journal of General Internal Medicine Vol. 28 (pp. S66). Denver, US: Springer Nature.
2012
Statins and associated risk of pneumonia: a systematic review and meta-analysis of observational studies (Journal article)
Kwok, C. S., Yeong, J. K. -Y., Turner, R. M., Cavallazzi, R., Singh, S., & Loke, Y. K. (2012). Statins and associated risk of pneumonia: a systematic review and meta-analysis of observational studies. European Journal of Clinical Pharmacology, 68(5), 747-755. doi:10.1007/s00228-011-1159-4DOI: 10.1007/s00228-011-1159-4
2011
A new anaesthetic receptacle (Journal article)
Turner, R. (2011). A new anaesthetic receptacle. Anaesthesia, 66(5), 401-402. doi:10.1111/j.1365-2044.2011.06745.xDOI: 10.1111/j.1365-2044.2011.06745.x
